Skip to main content
Equibles
LNAI logo

LNAI · Lunai Bioworks Inc. · Metrics

Track LNAI — free

Use LNAI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LNAI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.16 -0.07 (-30.17%) At close · Oct 29
Rebalance outlook locked
Going-concern doubt — flagged Oct 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the financial statements are issued. ... management has concluded that substantial doubt about the Company's ability to continue as a going concern has not been alleviated.”
View the 10-K filed Oct 13, 2026
Market Cap
$829,677
Shares
5.03M
Volume · Oct 29 1.28M Avg daily vol (3M) 394.64K

LNAI metrics

53 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.16
Market cap
$829,677

Price action

23 metrics
Price change (1W)
-64.9%
Price change (30D)
-84.9%
Price change (3M)
-91.8%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
153.4%
Annualized volatility (3M)
147.3%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
2.7
RSI (14D)
13.4
Price vs SMA 50
-89.7%
Price vs SMA 200
—
Avg volume (3M)
394,643
Relative volume
3.2
Average dollar volume
$481,905

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
5.03M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-429.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-16,729.4%
Trailing 12 months
Net margin
-6,852.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$8.70M
Net income (TTM)
−$3.56M
Trailing 12 months
Diluted EPS (TTM)
$-1.06
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-60.43
EBITDA per diluted share (TTM)
$-60.39
Net income per diluted share (TTM)
$-58.51
Operating cash flow per diluted share (TTM)
$-2.00
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.57
Book value per share
$-1.96

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+52.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-35.8%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$8.60M
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-37.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.71M
Total assets
$9.94M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$5.29M
Capital expenditures (TTM)
—
R&D (TTM)
$24,518
SG&A (TTM)
—
Stock compensation (TTM)
$630,389
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
16
13F filer change QoQ
-12
Institutional ownership
3.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
2.0%
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
+75.8%
Holder tenure
2.4
Price vs estimated holder cost
-63.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.6%

Short interest

3 metrics
Short interest
2.3%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
41 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1527728 CUSIP 29350E302 13F (30d) 2 filings 2 filers Visit website Investor relations